# A Phase 2a Pharmacodynamic Study of TAK-448 in Participants With Hypogonadotropic Hypogonadism

> **NCT02369796** · PHASE2 · TERMINATED · sponsor: **Takeda** · enrollment: 15 (actual)

## Conditions studied

- Hypogonadotropic Hypogonadism

## Interventions

- **DRUG:** TAK-448

## Key facts

- **NCT ID:** NCT02369796
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-02
- **Primary completion:** 2015-10
- **Final completion:** 2015-11
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Sponsor decision to terminate the study because the study did not achieve the primary efficacy objective.
- **Last updated:** 2017-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02369796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02369796, "A Phase 2a Pharmacodynamic Study of TAK-448 in Participants With Hypogonadotropic Hypogonadism". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02369796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*